FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “AC Immune SA Rises 70% on Alzheimer’s Drug Trial Results”
AC Immune SA (NASDAQ: ACIU) surged over 70% in premarket trading after announcing the first positive cognitive results for a Tau-Targeting Monoclonal Antibody in Alzheimer’s Disease.
Genentech, a member of the Roche Group, informed the Company that the Lauriet Phase 2 trial of semorinemab in mild-to-moderate AD shows a statistically significant reduction on one of two co-primary endpoints, ADAS-Cog11, and that the drug has been well tolerated with an acceptable safety profile and no unanticipated safety signals.
AC Immune SA is clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen ® and Morphomer ® , fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features ten therapeutic and three diagnostic candidates, six of which are currently in clinical trials. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies including Genentech, a member of the Roche Group, Eli Lilly and Company, and Janssen Pharmaceuticals, Inc., resulting in substantial non-dilutive funding to advance its proprietary programs and over $3 billion in potential milestone payments.
For more information, please visit: AC Immune SA
About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.
The post “The Buzz” Show: AC Immune SA (NASDAQ: ACIU) Alzheimer’s Drug Trial Results first appeared on Financial Buzz .
For further details see:
“The Buzz” Show: AC Immune SA (NASDAQ: ACIU) Alzheimer’s Drug Trial Results